Platelet Disorder Clinical Trial
Official title:
A Phase II Trial of Avatrombopag for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplant
Verified date | November 2021 |
Source | Ohio State University Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies the side effects and how well avatrombopag works for the treatment of thrombocytopenia after donor hematopoietic stem cell transplant. Thrombocytopenia is defined as abnormally low level of platelets in the blood. Avatrombopag is a small molecule thrombopoietin receptor agonist which stimulates thrombopoietin receptor leading to increase production of platelets.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Failure to engraft platelets by day 30 (D30) after hematopoietic cell transplantation (HCT) defined as: Platelet count less than 20,000/uL and patient is still dependent on platelet transfusion support - Patient must be able to start treatment with avatrombopag within 30-60 days following transplant - Able to provide written informed consent from patient or legal representative Exclusion Criteria: - Serious uncontrolled infections - Steroid refractory graft versus host disease (GVHD) - Patients with thrombotic microangiopathy - Pregnant or lactating women - Creatinine clearance < 30 ml/min - Active thromboembolism requiring anticoagulation - Unable to understand the investigational nature of the study or provide informed consent - Evidence of disease relapse by flow cytometry of chimerisms - Concomitant use of other thrombopoietin receptor agonists (TPO-RA) medication during the treatment phase of the study or two weeks prior to enrollment |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ayman Saad | Dova Pharmaceuticals |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of adverse events of avatrombopag treatment | Toxicities will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version (v).5 standard toxicity grading. Frequency and other descriptive statistics will be used to present the toxicity pattern. | Up to 30 days after the last dose | |
Primary | Failure rate of platelet recovery | The proportion will be provided with 95% exact binomial confidence interval. | At day 90 | |
Secondary | Independence from platelet transfusion | Up to 1 year | ||
Secondary | Duration of platelet response | Will be presented in a descriptive manner. | Up to 1 year | |
Secondary | Platelet count >= 50,000/uL for 7 consecutive days without transfusion support | Up to 1 year | ||
Secondary | Duration of exposure to avatrombopag | Will be presented in a descriptive manner. | Up to 1 year | |
Secondary | Incidence of adverse events associated with avatrombopag treatment | Up to 30 days after last dose | ||
Secondary | Transplant-related mortality | At day 100 and 1 year post-hematopoietic stem cell transplant (HCT) | ||
Secondary | Progression-free survival (PFS) of underlying malignant hematologic disorder | The method of Kaplan-Meier will be used to estimate PFS. | From the time of HCT to progression and death, assessed up to 1 year | |
Secondary | Overall survival (OS) | The method of Kaplan-Meier will be used to estimate OS. | From the time of HCT to death from any cause, assessed up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05985668 -
Towards Improved Diagnostics for Suspected Platelet Function Disorders
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02979158 -
Preoperative Dual Antiplatelet Therapy: Platelet Function and Influence of Cardiopulmonary Bypass
|
N/A | |
Recruiting |
NCT04842760 -
PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
|
||
Completed |
NCT01880047 -
Safety and Efficacy of Eltrombopag at Escalated Doses
|
Phase 2 | |
Recruiting |
NCT05143892 -
Avatrombopag to Promote Platelet Engraftment After Allo-HSCT
|
Phase 2 |